Article: Medical Science Systems Enters Into License Agreement with Glaxo Wellcome.

SAN ANTONIO--(BW HealthWire)--Dec. 7, 1998--

BioFusion(R) Technology Developed by Medical Science Systems

Will Support Compound Screening Efforts

Medical Science Systems, Inc. (NASDAQ Symbol: MSSI) announced today that it has entered into a development and license agreement with Glaxo Wellcome Inc., a subsidiary of Glaxo Wellcome plc (NYSE: GLX), to develop a computer model in support of new compound screening.

Medical Science Systems' BioFusion proprietary technology provides a means of developing computer-based simulation models of large, complex biological systems which can assist in the interpretation of gene expression and ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!